Nathan @ESMO2017

EORTC study results in poster presentations @ESMO 2017 in Madrid

EORTC experience with advanced/metastatic epithelioid sarcoma patients treated in prospective clinical trials: clinical profile and response to systemic therapy

Nathan Touati, an EORTC statistician fellow presented results on the“EORTC experience with advanced/metastatic epithelioid sarcoma patients treated in prospective clinical trials: clinical profile and response to systemic therapy”. Little is known about the clinical course and response to systemic treatments for epthelioid sarcomas (a soft tissue sarcoma associated with a high local recurrence rate after primary resection and high incidence of distant metastasis). Pooled data from 27 patients with locally advanced/ metastatic epithelioid sarcoma who entered in to EORTC prospective multi-sarcoma phase II/III trials was presented. With the limitations of such a small dataset, it was concluded that objective response and survival outcomes of this cancer are relatively poor. The clinical testing of novel agents remains a high priority. (Poster)

Evolution in neutrophil to lymphocyte ratio (NLR) among advanced Soft Tissue Sarcoma (STS) patients treated with pazopanib within EORTC 62043/62072 trials

Eleonora De Maio, an EORTC clinical research physician, presented the “Evolution in neutrophil to lymphocyte ratio (NLR) among advanced Soft Tissue Sarcoma (STS) patients treated with pazopanib within EORTC 62043/62072 trials”. The aim of this retrospective analysis was to confirm that a higher NLR ratio at baseline is associated with worse prognosis in STS and to evaluate if an early decline of NLR during treatment with pazopanib is associated with a more favourable prognosis. Out of the eligible patients treated with pazopanib, patients with a NLR≥3 were associated with shorter PFS and OS. In conclusion, the prognostic value of NLR at baseline was confirmed in advanced soft tissue sarcoma patients, irrespective of treatment. However, the changes in NLR during the first 50 days of treatment with pazopanib were not associated with patient outcome, hence cannot be used as an early marker for response. (Poster)

Diversity of brain metastasis management in Non-Small Cell Lung Cancer in Europe

The Young Investigators of EORTC Lung Cancer Group presented their survey on the diversity of brain metastasis management in Non-Small Cell Lung Cancer in Europe. They presented results of online survey that was sent to all EORTC Lung Cancer Group members as well as several EU societies involved in lung cancer treatment. 478 Physicians responded to the survey. They found that nearly 85% of the physicians screened neurologically asymptomatic patients for brain metastasis at diagnosis. Mostly physicians screened for stage III and Stage IV. They found that brain management differed in each European country and screening was not uniform. (Poster)

Assessment of the management and treatment strategies of elderly patients diagnosed with advanced Non-Small Cell Lung Cancer (NSCLC)

The EORTC Lung Cancer Group and Elderly Task Force also presented a pan- European survey that assessed the management and treatment strategies of elderly patients diagnosed with advanced Non-Small Cell Lung Cancer (NSCLC). 62 sites from 19 countries responded; the results show that there was no dedicated team in the management and treatment of elderly patients in 42 centres. In 2 centres, there was no discussion of patients who may potentially have NSCLC with a multidisciplinary team. It was noted that oncogeriatric assessment was routinely performed in only 17 centres. It was concluded that there was no standardised approach to the management and treatment of elderly patients with NSCLC and further research was needed in this area. (Poster)

EORTC HNCG/UKCRN 1206 randomised phase II study to evaluate the efficacy and safety of chemotherapy vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic androgen receptor (AR) expressing salivary gland cancer (SGC)

The EORTC Head and Neck Cancer Group presented a trial in progress abstract on the EORTC HNCG/UKCRN 1206 randomised phase II study to evaluate the efficacy and safety of chemotherapy vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic androgen receptor (AR) expressing salivary gland cancer (SGC). This study is a collaboration between EORTC Head and Neck Cancer group, taking the lead, and UNICANCER/REFCOR, International Rare Cancer Initiative UK, Salivary Gland Group and RARECARENet. It will run in 35 sites in 10 countries. The trial design includes at total 76 treatment naïve patients (Cohort A) who will be randomised to receive ADT or platinum-based chemotherapy. Previously treated patients will be enrolled in a separate Cohort B to receive ADT. Patients from Cohort A randomised to chemotherapy can enter Cohort B to receive ADT. Patients from Cohort A randomised to chemotherapy can enter Cohort B at disease progression. The primary endpoint is progression free survival for Cohort A and best overall response for Cohort B. Mechanisms and resistance of AR activation will be studied. (Poster)

Back to news list